title: Interview with Jürg Zimmermann, global head of oncology & exploratory chemistry at Novartis.
abstract: Dr Jürg Zimmermann is the inventor of the drug imatinib (Gleevec(®), Glivec(®)), which entered the market in 2001 and revolutionized the treatment of chronic myelogenous leukemia. He talks to Future Medicinal Chemistry about his career as a medicinal chemist, current issues in pharmaceutical R&D and his experiences of developing Gleevec, the first protein kinase to get onto market.
authors.affiliation: Novartis Pharma AG, Postfach, Basel, Switzerland. juerg.zimmermann@novartis.com
authors.forename: Jürg
authors.initials: J
authors.lastname: Zimmermann
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002626:Chemistry, Pharmaceutical / Q000639:trends; D020650:Combinatorial Chemistry Techniques; D055808:Drug Discovery; D004345:Drug Industry / Q000639:trends; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012108:Research Personnel; D000078329:Workforce
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate